Adesleukin with or without vaccine therapy in treating patients with locally advanced or metastatic melanoma

Journal of Drugs in Dermatology, May, 2007

Sponsors and Collaborators: Center for Cancer Care at Goshen Health System and National Cancer Institute (NCI). The purpose of this randomized phase III trial is to compare the effectiveness of aldesleukin with or without vaccine therapy in treating patients with stage III or stage IV melanoma.

Condition        Intervention                                 Phase

Melanoma (Skin)  Drug: aldesleukin                            Phase III
                 Drug: gp100 antigen
                 Drug: incomplete Freund's adjuvant
                 Procedure: biological therapy
                 Procedure: cytokine therapy
                 Procedure: interleukin therapy
                 Procedure: nonspecific immune-modulator
                   therapy
                 Procedure: nontumor cell derivative vaccine
                 Procedure: vaccine therapy

Study ID Numbers: CDR0000066963; CCCGHS-NCI-T98-0085; NCI-T98-0085; NCI-99-C-0051B

ClinicalTrials.gov Identifier: NCT00019682